文献速递胸部肿瘤放疗放疗物理与技术

疗前与疗中代谢肿瘤体积预测局部晚期非小细胞肺癌根治性放疗后病灶局部复发

Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume.
PubMed 文献 · Radiat Oncol · 2020-05-19

该回顾性研究纳入2006至2018年接受根治性放疗(剂量≥60 Gy)的III期非小细胞肺癌患者,测量疗前和疗中PET-CT的代谢肿瘤体积(MTV),评估其与病灶局部复发(LR)的关联。结果显示疗前和疗中MTV均能预测LR,且疗中MTV预测能力更强,可能有助于疗中识别高危病灶以指导剂量雕刻策略。

要点

  • 疗前和疗中MTV均与病灶局部复发显著相关,疗中MTV预测能力更高。
  • 基于疗前MTV低危的病灶中,疗中MTV升高仍与局部复发相关。
  • 疗中MTV或可帮助筛选高危病灶以指导剂量雕刻,但需验证。

核心结论

  • 病灶水平上,较大的疗前MTV和疗中MTV均预测局部复发风险增加。
  • 疗中MTV对局部复发的预测能力高于疗前MTV,若经验证可能有助于疗中区分高危病灶并指导剂量雕刻策略。

研究设计与样本

  • 回顾性队列研究,纳入2006至2018年接受根治性放疗(剂量≥60 Gy)的III期非小细胞肺癌患者,共111例患者、387个病灶(112个肺肿瘤和275个淋巴结)。
  • 测量疗前和疗中PET-CT上治疗病灶的MTV(MTVpre和MTVmid),局部复发定义为病灶在计划靶区内的复发。
  • 采用ROC曲线、累积发生率以及单因素和多因素竞争风险回归评估MTV与局部复发的关联。

主要发现

  • 中位年龄68岁,男性占69.4%,腺癌占46.8%,鳞癌占39.6%,95.5%接受同步化疗,中位随访38.7个月。
  • 3年总生存率为42.3%,3年局部复发累积发生率按患者为26.8%,按病灶为11.9%。
  • MTVpre和MTVmid预测局部复发的ROC曲线下面积分别为0.71和0.76。
  • 多因素分析中MTVpre和MTVmid均与局部复发显著相关(P=0.004和P=7.1e-5)。
  • 在基于MTVpre判定为低危的病灶中,较高的MTVmid仍与局部复发相关(P=0.001)。

临床怎么用

  • 疗前和疗中PET-CT测量的MTV可用于评估病灶局部复发风险。
  • 疗中MTV可能帮助在放疗中途识别高危病灶,为剂量雕刻策略提供依据,但需进一步验证。

局限性

  • 回顾性研究设计。
  • 结论中提及疗中MTV的预测价值需验证后方可用于指导剂量雕刻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated whether pre- and mid-treatment metabolic tumor volume (MTV) predicts per lesion local recurrence (LR) in patients treated with definitive radiation therapy (RT, dose≥60 Gy) for locally advanced non-small cell lung cancer (NSCLC). METHODS: We retrospectively reviewed records of patients with stage III NSCLC treated from 2006 to 2018 with pre- and mid-RT PET-CT. We measured the MTV of treated lesions on the pre-RT (MTVpre) and mid-RT (MTVmid) PET-CT. LR was defined per lesion as recurrence within the planning target volume. Receiver operating characteristic (ROC) curves, cumulative incidence rates, and uni- and multivariable (MVA) competing risk regressions were used to evaluate the association between MTV and LR. RESULTS: We identified 111 patients with 387 lesions (112 lung tumors and 275 lymph nodes). Median age was 68 years, 69.4% were male, 46.8% had adenocarcinoma, 39.6% had squamous cell carcinoma, and 95.5% received concurrent chemotherapy. Median follow-up was 38.7 months. 3-year overall survival was 42.3%. 3-year cumulative incidence of LR was 26.8% per patient and 11.9% per lesion. Both MTVpre and MTVmid were predictive of LR by ROC (AUC = 0.71 and 0.76, respectively) and were significantly associated with LR on MVA (P = 0.004 and P = 7.1e-5, respectively). Among lesions at lower risk of LR based on MTVpre, higher MTVmid was associated with LR (P = 0.001). CONCLUSION: Per-lesion, larger MTVpre and MTVmid predicted for increased risk of LR. MTVmid was more highly predictive of LR than MTVpre and if validated may allow for further discrimination of high-risk lesions at mid-RT informing dose painting strategies.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Binkley MS, Koenig JL, Kashyap M, et al. Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume. Radiat Oncol. 2020. PMID: 32429982. doi:10.1186/s13014-020-01546-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。